Reuters01-13
Jan 13 (Reuters) - Simcere Pharmaceutical 2096.HK said on Monday its unit had granted U.S. drugmaker AbbVie ABBV.N the option to license its new blood cancer drug candidate outside China.
Under the deal, AbbVie will pay Simcere up to $1.06 billion, along with royalties on sales outside China. AbbVie would receive royalties on sales within China.
(Reporting by Aaditya Govind Rao in Bengaluru; Editing by Vijay Kishore)
((Aaditya.GovindRao@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
抱歉，当前请求异常(-1)
Australian Rare Earths Ltd-Proposed Issue of Securities - Ar3
Comet Ridge Ltd - Mahalo Jv Engages Jemena for Pipeline Feed
Auking Mining Ltd-Cloncurry Project Proposed Drilling Program
Chimeric Therapeutics - US Patent Allowed for Chm Cdh17 Technology
Hyundai Steel: Plant Capacity Expected to Be 2.7 Million Tonnes Annually
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial